Skip to main page content
U.S. flag

An official website of the United States government

Dot gov

The .gov means it’s official.
Federal government websites often end in .gov or .mil. Before sharing sensitive information, make sure you’re on a federal government site.

Https

The site is secure.
The https:// ensures that you are connecting to the official website and that any information you provide is encrypted and transmitted securely.

Access keys NCBI Homepage MyNCBI Homepage Main Content Main Navigation
Review
. 2011 Jun;30(2):127-37.
doi: 10.1016/j.sder.2011.05.001.

Pruritus: management algorithms and experimental therapies

Affiliations
Review

Pruritus: management algorithms and experimental therapies

Martin Steinhoff et al. Semin Cutan Med Surg. 2011 Jun.

Abstract

Pruritus (itch) is a major symptom in many dermatologic as well as systemic diseases and has a dramatic impact on the quality of life in these patients. The symptom of itch has to be treated on the basis of its pathophysiology and its underlying disease. In daily practice, a "quick" diagnosis of the underlying disease is often difficult, although a rapid relief of the itch is desired. We often treat patients on the basis of the symptomatology. A rational therapeutic ladder for a symptomatic therapy is useful until the final diagnosis has been confirmed. There are probably many subtypes of pruritus, just as there are many diseases that cause itch. The pathophysiology in many subtypes of pruritus is still poorly understood, hindering a rapid and targeted treatment strategy. An extensive diagnostic workup is often required to determine the final cause(s) of the itch. Thus, in daily life, physicians often start with a more or less rational therapeutic strategy to combat the debilitating itch. We present possible therapeutic ladders that form the basis for effective therapeutic itch strategies in various diseases. On the basis of our current knowledge about the different pathophysiologies of itch, on clinical trials or case reports, and our own clinical experience, we aim to present therapeutic ladders for the rapid as well as long-term management of itch. Finally, we summarize current exciting developments of experimental strategies in itch research and in clinical development for itch therapy.

PubMed Disclaimer

Conflict of interest statement

The authors have nothing to disclose and no conflicts of interest to report. Dr. Steinhoff has performed consultancy services for which he received compensation for Galderma, Merck, Sanofi-Aventis and Regeneron. On behalf of Dr. Steinhoff, his institution has received financial gifts from Maruho (Japan), and research was supported by ZymoGenetics, L’Oreal and Galderma.

References

    1. Suárez AL, Feramisco JD, Koo J, et al. Psychoneuroimmunology of psychological stress and atopic dermatitis: Pathophysiologic and therapeutic updates. Acta Derm Venereol. in press. - PMC - PubMed
    1. Lynde CB, Kraft JN, Lynde CW. Novel agents for intractable itch. Skin Ther Lett. 2008;13:6–9. - PubMed
    1. Darsow U, Wollenberg A, Simon D, et al. ETFAD/EADV eczema task force 2009 position paper on diagnosis and treatment of atopic dermatitis. J Eur Acad Dermatol Venereol. 2010;24:317–328. - PubMed
    1. Curtis AR, Tegeler C, Burdette J, et al. Holistic approach to treatment of intractable central neuropathic itch. J Am Acad Dermatol. 2011;64:955. - PubMed
    1. Patel T, Yosipovitch G. Therapy of pruritus. Exp Opin Pharmacother. 2010;11:1673–1682. - PMC - PubMed